Can I read Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial on EtoBox?

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial by Matthew G. Johnson; Julie M. Strizki; Michelle L. Brown; Hong Wan; Hala H. Shamsuddin; Moti Ramgopal; Diana F. Florescu; Pierre Delobel; Ilsiyar Khaertynova; José F. Flores; Leon F. Fouche; Shan-Chwen Chang; Angela Williams-Diaz; Jiejun Du; Jay A. Grobler; Amanda Paschke; Carisa De Anda is a Medicine article available to read on EtoBox.

What is Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial about?

## Abstract ## Purpose Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT trial. ## Methods In phase 3 of MOVe-OUT, non-hospitalized at-risk adults with mild-to-moderate COVID-19 were randomized to receive molnupiravir 800 mg or placebo twice daily for 5 days. Immunocompromised participants were identified based on prior/concomitant medications and/or medical history. All-cause hospitalization/death, adverse events, SARS-CoV-2 titers, infectivity, and RNA sequences were compared between immunocompromised participants who received molnupiravir or placebo and with non-immunocompromised participants. ## Results Fifty-five of 1408 participants were considered immunocompromised. Compared to placebo, fewer molnupiravir-treated immunocompromised participants were hospitalized/died through Day 29 (22.6% [7/31] vs. 8.3% [2/24]), with fewer adverse events (45.2% [14/31] vs. 25.0% [6/24]). A larger mean change from baseline in SARS-CoV-2 RNA was observed with molnupiravir compared to placebo in non-immunocompromised

Who reads Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial?

Author

Matthew G. Johnson; Julie M. Strizki; Michelle L. Brown; Hong Wan; Hala H. Shamsuddin; Moti Ramgopal; Diana F. Florescu; Pierre Delobel; Ilsiyar Khaertynova; José F. Flores; Leon F. Fouche; Shan-Chwen Chang; Angela Williams-Diaz; Jiejun Du; Jay A. Grobler; Amanda Paschke; Carisa De Anda

Publisher

Springer Science and Business Media LLC

Published

2023

Language

EN

Field

Medicine (Health Sciences)